NCT01580748

Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: Seoul National University Bundang Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

There is currently no effective treatment of bronchiectasis other than treating its complications such as infection, bleeding, etc. Roflumilast is a newly developed anti-inflammatory drug that has proven to be effective in stable COPD. We hypothesized that Roflumilast might be effective in symptomatic bronchiectasis patients

Conditions

• Symptomatic Bronchiectasis

Interventions

Type	Name	Description
DRUG	Roflumilast	500 microgram once daily for 16 weeks

Timeline

• Start date: 2012-05-01
• Primary completion: 2012-12-01
• Completion: 2013-01-01
• First posted: 2012-04-19
• Last updated: 2012-04-19

Locations

1 site across 1 country: South Korea